MRKR:NASDAQMarker Therapeutics, Inc. analysis
Data as of Oct 13, 2026 - not real-time
- Latest price
- $0.92
- Risk: high
- 9/10High risk
Summary
Marker Therapeutics, Inc. is priced at $0.9249 and its moving averages line up in bearish order, the shorter trailing the longer. The last 30 days have lost 30.5%. Relative strength is 32.4 — approaching oversold — and the MACD signal is bearish. Watch $0.9100 as support and $1.31 as the nearer resistance level.
The company is not currently profitable on a trailing basis, so earnings multiples offer no valuation support. The average analyst target implies 750.5% above today's level.
Risk scores 9 out of 10, which is high for this asset class. With 30-day volatility of 59.8%, a beta of 1.02 and a maximum drawdown of 57.8%, position sizing matters more than entry timing here. Thin trading volumes mean execution costs can be material on larger orders. The wider market backdrop reads extreme greed at 94 on the fear-greed composite.
Timeframes disagree: the short-term read is sell while the long-term read is hold, conviction 2 out of 10.
The company is not currently profitable on a trailing basis, so earnings multiples offer no valuation support. The average analyst target implies 750.5% above today's level.
Risk scores 9 out of 10, which is high for this asset class. With 30-day volatility of 59.8%, a beta of 1.02 and a maximum drawdown of 57.8%, position sizing matters more than entry timing here. Thin trading volumes mean execution costs can be material on larger orders. The wider market backdrop reads extreme greed at 94 on the fear-greed composite.
Timeframes disagree: the short-term read is sell while the long-term read is hold, conviction 2 out of 10.
Top market events
- HOUSTON, Sept. 22, 2026 GLOBE NEWSWIRE -- Marker Therapeutics, Inc. Nasdaq: MRKR , a clinical-stage immuno-oncology...
Market outlook
Short term
< 1 yearCautious
Model confidence4/104 out of 10
Key factors
- Short-term moving averages stacked below long-term ones
- Trading below the 200-day average of 1.42
- MACD momentum is negative
Medium term
1–3 yearsNeutral
Model confidence3/103 out of 10
Key factors
- Short-term moving averages stacked below long-term ones
- Trading below the 200-day average of 1.42
- Analyst targets imply +750.5% versus the current price
Long term
> 3 yearsNeutral
Model confidence2/102 out of 10
Key factors
- Negative profit margin of -245.5%
- Analyst targets imply +750.5% versus the current price
- Negative return on equity of -76.9%
Key metrics
Financial health
Profit Margin-245.51%
P/E Ratio-1.7
ROE-76.87%
ROA-40.47%
P/B Ratio1.3
Op. Cash Flow$-9756497
Free Cash Flow$-6227035
Industry P/E30.3
Technical analysis
TrendBearish
RSI32.4
Support$0.91
Resistance$1.31
MA 20$1.09
MA 50$1.18
MA 200$1.42
MACDBearish
VolumeIncreasing
Fear & Greed Index94.14
Valuation
Target Price$7.87
Upside/Downside750.54%
GradeFair
TypeBlend
Risk assessment
Beta1.02
Volatility59.78%
Sector RiskMedium
Reg. RiskHigh
Geo RiskLow
Currency RiskLow
Liquidity RiskHigh
Similar tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.